Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2012 Aug 31;11(1):57–62. doi: 10.1016/j.cgh.2012.08.032

Table 3.

Risk of CD and UC, According to Baseline MHI-5a

MHI-5 score
86–100		 MHI-5 score
76–85		 MHI-5 score
53–75		 Depressive symptoms
0–52		 P linear
trend
Person-years of follow-up 385,462 632,548 570,487 198,573
CD
 No. of cases 32 54 59 25
 Age-adjusted incidenceb 8 9 10 13
 Age-adjusted HR (95% CI) 1.0 1.11 (0.72–1.73) 1.39 (0.90–2.16) 1.75 (1.03–2.99) .02
 Multivariate HR (95% CI)c 1.0 1.09 (0.70–1.69) 1.33 (0.86–2.06) 1.62 (0.95–2.77) .04
UC
 No. of cases 38 70 73 22
 Age-adjusted incidenceb 10 11 13 11
 Age-adjusted HR (95% CI) 1.0 1.10 (0.74–1.65) 1.25 (0.84–1.87) 1.11 (0.65–1.89) .55
 Multivariate HR (95% CI)c 1.0 1.09 (0.73–1.62) 1.22 (0.82–1.82) 1.07 (0.63–1.83) .66
a

Remote depressive symptoms refer to MHI-5 administered in 1992 (NHS I) or in 1993 (NHS II).

b

Per 100,000 person-years.

c

Adjusted for age, cohort, race (white, nonwhite), smoking (never, past, current), BMI (<20, 20–24.9, 25–29, ≥30 kg/m2), oral contraceptive use (never, past, current), use of PMH therapy (premenopausal, PMH never user, past user, current user), regular use of NSAIDs (yes, no), regular use of aspirin (yes, no).